Evidence map›Paper›PMID 30999004›Full record

ArticleMetabolism: clinical and experimental2019

Lipoxygenase drives lipidomic and metabolic reprogramming in ischemic heart failure.

Ganesh V Halade, Vasundhara Kain, Bochra Tourki, Jeevan Kumar Jadapalli

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Metabolism: clinical and experimental, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
3.5field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Extrinsic and intrinsic modulators of inflammation-resolution signaling in heart failure.American journal of physiology. Heart and circulatory physiology · 2023
    Review
  9. Article
  10. Circulating sphingolipids in heart failure.Frontiers in cardiovascular medicine · 2023
    Review
  11. Article
  12. Role of cellular retinol-binding protein, type 1 and retinoid homeostasis in the adult mouse heart: A multi-omic approach.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2022
    Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Ganesh V HaladeDivision of Cardiovascular Disease, Department of Medicine, The University of Alabama at Birmingham, AL, United States. Electronic address: ganeshhalade@uab.edu.
Vasundhara KainDivision of Cardiovascular Disease, Department of Medicine, The University of Alabama at Birmingham, AL, United States.
Bochra TourkiDivision of Cardiovascular Disease, Department of Medicine, The University of Alabama at Birmingham, AL, United States.
Jeevan Kumar JadapalliDivision of Cardiovascular Disease, Department of Medicine, The University of Alabama at Birmingham, AL, United States.
University of Alabama at Birmingham · USUniversity of Alabama at Birmingham Hospital · US

Funding

Resolution of Inflammation in Heart Failure Post-Myocardial InfarctionR01HL132989 · NHLBI · UNIVERSITY OF SOUTH FLORIDA · PI HALADE, GANESH V · 2016 to 2020
$1.8M
DHA Mechanisms in Obesity-mediated Cardiac Remodeling Post-Myocardial InfarctionR00AT006704 · NCCIH · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI HALADE, GANESH V · 2013 to 2015
$717k
NCCIH NIH HHS R00 AT006704NHLBI NIH HHS R01 HL132989
6 · The paper itself

Abstract

backgroundAfter myocardial infarction (MI), delayed progression or reversal of cardiac remodeling is a prime target to limit advanced chronic heart failure (HF). However, the temporal kinetics of lipidomic and systemic metabolic signaling is unclear in HF. There is no consensus on metabolic and lipidomic signatures that influence structure, function, and survival in HF. Here we use genetic knock out model to delineate lipidomic, and metabolic changes to describe the role of lipoxygenase in advancing ischemic HF driven by leukocyte activation with signs of non-resolving inflammation. Bioactive lipids and metabolites are implicated in acute and chronic HF, and the goal of this study was to define the role of lipoxygenase in temporal kinetics of lipidomic and metabolic reprogramming in HF. MATERIALS AND

methodsTo address this question, we used a permanent coronary ligation mouse model which showed profound metabolic and lipidomic reprogramming in acute HF. Additionally, we defined the lipoxygenase-mediated changes in cardiac pathophysiology in acute and chronic HF. For this, we quantitated systemic metabolic changes and lipidomic profiling in infarcted heart tissue with obvious structural remodeling and cardiac dysfunction progressing from acute to chronic HF in the survival cohort.

resultsAfter MI, lipoxygenase-derived specialized pro-resolving mediators were quantitated and showed lipoxygenase-deficient mice (12/15LOX

conclusionSpecific lipoxygenase deletion alters lipidomic and metabolic signatures, with modified leukocyte profiling that delayed HF progression and improved survival. Future studies are warranted to define the molecular network of lipidome and metabolome in acute and chronic HF patients.

Indexed as

Lipidomics2-Aminoadipic AcidAnimalsBiomarkersCoronary VesselsHeartHeart FailureKineticsLeukocytesLigationLipid MetabolismLipoxygenasesMiceMice, Inbred C57BLMice, KnockoutMyocardial Ischemia2-Aminoadipic AcidBiomarkersLipoxygenasesHeart failureLeukocytesLipid mediatorsMetabolic signalingMetabolitesResolution of inflammation

Identifiers

PMID30999004
PMCPMC12962181
OpenAlexW2937781285

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.